NanoVibronix Inc, listed as NAOV on the NASDAQ, has released positive findings from a recent UroShield study conducted at the University of Southampton in the United Kingdom.
The study reveals that UroShield, a device that utilizes ultrasonic waves to form an acoustic shield on catheter surfaces, has shown promising results in reducing catheter-associated urinary tract infections (CAUTI) and catheter blockages. Approximately one-third of the study participants experienced a decrease in the frequency of catheter blockages and the need for unscheduled catheter changes.
In addition to quantitative data, qualitative data collected from participants also indicates favorable opinions and confirms the positive impact of UroShield.
Notably, UroShield’s ultrasonic waves disrupt bacteria attachment, inhibiting biofilm formation and the development of infections. This technology has the potential to reduce or eliminate the need for antibiotics, while also preventing biofilm formation, reducing bacteriuria/UTI, alleviating catheter pain and discomfort, and enhancing the effectiveness of antibiotics.
At the time of this update on Wednesday, NAOV shares are trading at $2.84, representing a significant increase of 95.90%.